Last reviewed · How we verify
NCT03376763: MAESTRO
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Phase 4 trial testing Abilify maintena in Schizophrenia in 201 participants. Completed in 19 November 2021.
19 November 2021
Quick facts
| Lead sponsor | Korea Otsuka Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 201 |
| Start date | 21 November 2017 |
| Primary completion | 19 November 2021 |
| Estimated completion | 19 November 2021 |
| Sites | 27 locations across South Korea |
Drugs / interventions tested
- Abilify maintena — full drug profile →
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Antipsychotics — all drugs for Antipsychotics →
- Long-Acting Injection — all drugs for Long-Acting Injection →
- LAI — all drugs for LAI →
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 19 to 64, any sex, with Schizophrenia or Antipsychotics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interventional, multicenter, open-label, 20 weeks study * To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena. * To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03376763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Korea Otsuka Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06674291 — Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive M · not yet recruiting
- NCT05048069 — Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. · unknown
- NCT04189705 — A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis · Phase 3 · completed
- NCT04150146 — To Evaluate Food Effect on the Pharmacokinetics of Rebamipide in Healthy Volunteers · Phase 1 · completed
- NCT03949894 — Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domI · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03376763 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea Otsuka Pharmaceutical Co., Ltd.
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03376763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing